Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

ReutersMar 25, 2025 11:45 AM

March 25 (Reuters) - Axsome Therapeutics Inc AXSM.O:

AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINT
AXSOME THERAPEUTICS INC: WELL TOLERATED WITH SAFETY PROFILE GENERALLY CONSISTENT WITH PRIOR SOLRIAMFETOL TRIALS
AXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBO
AXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Brent Spot $190 Warning: WTI Flips Global Benchmark in Rare Price Inversion as Geopolitical Tensions Flare

TradingKey - Since April, as the conflict in the Middle East has continued to escalate, the oil market has undergone a dramatic transformation: WTI crude has been repriced, not only matching the performance of the global benchmark Brent crude but also surpassing it during several trading sessions. O

Today’s Market Recap: U.S. Stocks Gain on Iran Peace Oververtures; Oracle Jumps 12% Marking Best Day Since Sept; Software Sector Sees Across-the-Board Gains

TradingKey - On Monday Eastern Time, the three major U.S. stock indices closed higher, driven by expectations of easing tensions in the Middle East. The S&P 500 rose 1.02% to close at 6,886, recovering losses since the outbreak of the U.S.-Iran war. The Nasdaq Composite climbed 1.23% to end at 23,18

Palantir vs. Anthropic: The Niche Battle Even Trump’s Endorsement Cannot Stop

TradingKey — On April 10, 2026, U.S. President Donald Trump posted a high-profile message on Truth Social that drew significant attention on Wall Street, directly naming and praising data analytics firm Palantir Technologies. He wrote: "Palantir Technologies (PLTR) has proven to have powerful combat capabilities and equipment. Just ask our enemies!!!" According to TheStreet, Trump’s rare inclusion of the stock ticker makes him the first president in U.S. history to publicly mention a specific stock by its ticker symbol.

Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Elon Musk’s XChat, the Western equivalent of WeChat, is set to launch on the App Store, issuing a direct challenge to giants such as Meta, Apple, and PayPal.

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Microsoft at $370 is a 17%-revenue-growth, 47%-margin, $625-billion-backlog business trading at a multi-year low valuation, because the market is scared of macro noise. The AI model releases this week prove the moat is deepening, not narrowing.

Featured Tools